EMMA (Emmaus Life Sciences) Effective Interest Rate on Debt %: 26.27% (As of Mar. 2026)


What is Emmaus Life Sciences Effective Interest Rate on Debt %?

Emmaus Life Sciences EMMA -7.26% Effective Interest Rate on Debt % is 26.27% as of Mar. 2026. The stock has 6 warning signs investors should review.

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Emmaus Life Sciences's annualized positive value of Interest Expense for the quarter that ended in Mar. 2026 was $8.50 Mil. Emmaus Life Sciences's average total debt for the quarter that ended in Mar. 2026 was $32.38 Mil. Therefore, Emmaus Life Sciences's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2026 was 26.27%.

Emmaus Life Sciences  (OTCPK:EMMA) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.

Emmaus Life Sciences Effective Interest Rate on Debt % Related Terms

Emmaus Life Sciences Effective Interest Rate on Debt % Historical Data

* Premium members only.

The historical data trend for Emmaus Life Sciences's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emmaus Life Sciences Effective Interest Rate on Debt % Chart

Emmaus Life Sciences Annual Data
Trend Sep16 Sep17 Sep18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Effective Interest Rate on Debt %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.98 18.84 22.98 16.55 21.78

Emmaus Life Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.24 20.54 24.11 28.25 26.27

EMMA vs PTIX, BZYR, RMTG: Effective Interest Rate on Debt % Comparison

For the Biotechnology subindustry, Emmaus Life Sciences's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Emmaus Life Sciences Effective Interest Rate on Debt % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Emmaus Life Sciences's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Emmaus Life Sciences's Effective Interest Rate on Debt % falls into.


Emmaus Life Sciences Effective Interest Rate on Debt % Calculation

Emmaus Life Sciences's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2025 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2024 )+Total Debt  (A: Dec. 2025 ))/ count )
=-1  *  -7.134/( (32.963+32.559)/ 2 )
=-1  *  -7.134/32.761
=21.78 %

where

Total Debt  (A: Dec. 2024 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=3.061 + 29.902
=32.963

Total Debt  (A: Dec. 2025 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=3.68 + 28.879
=32.559

Emmaus Life Sciences's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2026 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Dec. 2025 )+Total Debt  (Q: Mar. 2026 ))/ count )
=-1  *  -8.504/( (32.559+32.193)/ 2 )
=-1  *  -8.504/32.376
=26.27 %

where

Total Debt  (Q: Dec. 2025 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=3.68 + 28.879
=32.559

Total Debt  (Q: Mar. 2026 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=3.601 + 28.592
=32.193

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Mar. 2026) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.

What does a Effective Interest Rate on Debt % of 26.27% mean?
Emmaus Life Sciences (EMMA) has a Effective Interest Rate on Debt % of 26.27% as of Mar. 2026. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Emmaus Life Sciences and its competitors.
Is Emmaus Life Sciences' Effective Interest Rate on Debt % too high?
Emmaus Life Sciences' current Effective Interest Rate on Debt % is 26.27%.
How does Emmaus Life Sciences' Effective Interest Rate on Debt % compare to PTIX and BZYR?
Emmaus Life Sciences' Effective Interest Rate on Debt % of 26.27% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Effective Interest Rate on Debt % for a Biotechnology company?
A good Effective Interest Rate on Debt % depends on the Biotechnology industry context. However, Effective Interest Rate on Debt % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Effective Interest Rate on Debt % mean?
A high Effective Interest Rate on Debt % can signal that a stock is expensive relative to its fundamentals. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Emmaus Life Sciences and its competitors. Emmaus Life Sciences's current Effective Interest Rate on Debt % is 26.27%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emmaus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Emmaus Life Sciences (EMMA) is currently considered Fairly Valued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 8.5% above its estimated fair value. The current Effective Interest Rate on Debt % is 26.27%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Effective Interest Rate on Debt % calculated?
Effective Interest Rate on Debt % is calculated from a company's financial statements. For Emmaus Life Sciences (EMMA), the current Effective Interest Rate on Debt % is 26.27% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Emmaus Life Sciences Business Description

Address 21250 Hawthorne Boulevard, Suite 800, Torrance, CA, USA, 90503
Emmaus Life Sciences Inc is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sales of the Company's product Endari (prescription grade L-glutamine oral powder), to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari is reimbursable by the Centers for Medicare and Medicaid Services, and every state provides coverage for Endari for outpatient prescriptions to all eligible Medicaid enrollees within their state Medicaid programs. Endari is also reimbursable by many commercial payors.